A carregar...
Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Approximately 20% of pancreatic ductal adenocarcinoma (PDAC) patients have (borderline) resectable pancreatic cancer [(B)RPC] at diagnosis. Upfront resection with adjuvant chemotherapy has long been the standard of care for these patients. However, although surgical quality has improved, still about...
Na minha lista:
| Publicado no: | Front Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7005204/ https://ncbi.nlm.nih.gov/pubmed/32083002 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00041 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|